Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled Trial
RNA-seq (gene expression) · human · 32 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 32 samples: 32 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled TrialInternational journal of molecular sciences · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE252145_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1057887 and SRA study SRP480345. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 32 sample titles: 32 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7995132 Subject 1 pre treatment
- GSM7995133 Subject 1 post treatment
- GSM7995134 Subject 2 pre treatment
- GSM7995135 Subject 2 post treatment
- GSM7995136 Subject 4 pre treatment
- GSM7995137 Subject 4 post treatment
- GSM7995138 Subject 7 pre treatment
- GSM7995139 Subject 7 post treatment
- GSM7995140 Subject 8 pre treatment
- GSM7995141 Subject 8 post treatment
- GSM7995142 Subject 14 pre treatment
- GSM7995143 Subject 14 post treatment
- GSM7995144 Subject 15 pre treatment
- GSM7995145 Subject 15 post treatment
- GSM7995146 Subject 16 pre treatment
- GSM7995147 Subject 16 post treatment
- GSM7995148 Subject 20 pre treatment
- GSM7995149 Subject 20 post treatment
- GSM7995150 Subject 23 pre treatment
- GSM7995151 Subject 23 post treatment
- GSM7995152 Subject 24 pre treatment
- GSM7995153 Subject 24 post treatment
- GSM7995154 Subject 31 pre treatment
- GSM7995155 Subject 31 post treatment
- GSM7995156 Subject 38 pre treatment
- GSM7995157 Subject 38 post treatment
- GSM7995158 Subject 41 pre treatment
- GSM7995159 Subject 41 post treatment
- GSM7995160 Subject 49 pre treatment
- GSM7995161 Subject 49 post treatment
- GSM7995162 Subject 56 pre treatment
- GSM7995163 Subject 56 post treatment
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE282132 Early immune responses in the lung and blood following a randomized controlled human inhaled infection with aerosolized attenuated Mycobacterium Bovis BCG in healthy, BCG-naïve, UK adults 12 samples shares randomized, controlled, following
- GSE179224 A phase 2 Randomized Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients 4 samples shares randomized, controlled, treatment
- GSE299820 Innate immune epigenomic landscape following controlled human influenza virus infection 755 samples shares controlled, following
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.